Sweden: Alligator evaluating financing alternatives to support phase II studies

Alligator Bioscience, a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, is evaluating potential financing alternatives, which may include issuance of equity, in order to progress development plans. The board has assessed that working capital will need to be strengthened in order to enable phase II studies for Mitazalimab, phase II preparations and development of…

You must be a HMI Subscriber to view this content.

Subscribe Now »